Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$190.27 ▲ +1.55
(+0.82%)
MKT CAP: $40.78B • VOL: 1.32M
52W L $57 52W H $224
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$160
MEDIAN
$213
MEAN
$217
HIGH
$259
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RVMD TAPE
RVMD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $230.23 | $218.81 | 2025-02-14 | $173.15 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $239.74 | $224.52 | 2025-02-06 | $178.85 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $216.91 | $209.30 | 2025-01-29 | $182.66 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $194.08 | — | 2025-01-17 | $186.46 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $167.44 | $180.76 | 2025-01-09 | $169.34 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $226.42 | $197.88 | 2024-12-18 | $165.53 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $184.56 | $192.17 | 2024-12-04 | $176.95 | -4.3% | 48% | C |